<DOC>
	<DOCNO>NCT00578734</DOCNO>
	<brief_summary>Treatment lucinactant , peptide-containing synthetic lung surfactant , evaluate young child acute respiratory failure require mechanical ventilation ( life support ) , determine safe treatment lucinactant reduce number day child needs mechanical ventilation ( life support ) .</brief_summary>
	<brief_title>Lucinactant Treatment Acute Hypoxemic Respiratory Failure Children Two Years Old</brief_title>
	<detailed_description>Determine safety tolerability administration peptide-containing synthetic lung surfactant , lucinactant , child two year age assess whether treatment lucinactant decrease duration mechanical ventilation young child .</detailed_description>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<criteria>≥ 38 week ( correct age ) 2 year ( 24 month ) Intubated mechanically ventilate ( MV ) ≥ 6 hour anticipate need MV ≥ 24 hour Persistent hypoxia Written inform consent Mechanical Ventilation &gt; 48 hour Oxygenation index ≥ 25 , arterial line avialable Preexisting clinically significant palliated/uncorrected cardiac disease adversely affect cardiopulmonary function gas exchange Neuromuscular disease hypotonia Upper airway disease Baseline requirment supplemental oxygen Untreated pneumothorax Offlabel use commercially available surfactant outside neonatal period History prematurity passive immunoprophylaxis humanize monoclonal antibody Head injury Glasgow Coma Scale &lt; 8 Brain death impend brain death Do resuscitate order Cardiopulmonary resuscitation within 6 hour meet entry criterion Experimental therapy intervention potentially affect respiratory outcome Any transplant recipient Meconium aspiration syndrome Bordetella pertussis infection confirm via laboratory test and/or highly suspect pertussis infection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>